Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR The (un)usual suspects – how early detection research embraces interdisciplinary science August 20, 2021 Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis September 15, 2025 Reflections from our chief clinician: The essential role of our research... February 4, 2022 How CRISPR is Changing Cancer Research and Treatment July 27, 2020 Load more HOT NEWS FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung...
